Yahoo Finance

Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 results, provided an update on the Amtagvi launch, and highlighted pipeline progress and upcoming catalysts, the analyst tells investors in a research note. The firm says the Amtagvi launch hits total revenue target, but leaned on Proleukin contribution.

Discover the Best Stocks and Maximize Your Portfolio:

• See what stocks are receiving Strong Buy ratings from top-rated analysts.

• Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on IOVA:

• Iovance Biotherapeutics: Strong Financial Performance and Promising Clinical Advancements Drive Buy Rating

• Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges

• Iovance Biotherapeutics price target lowered to $20 from $24 at Baird

• Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler

• Iovance Biotherapeutics: Promising Growth Prospects and Strategic Focus Justify Buy Rating